Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
← catalyst calendarSponsored by Celyad Oncology SA (industry) · CYAD.BR — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18actual
Sites
5
Countries
Belgium, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-16 | actual | When the study began enrolling |
| Primary completion | 2022-12-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2037 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-08-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapse/Refractory Multiple Myeloma
Interventions
- Biological: CYAD-211
- Drug: Endoxan — also filed as cyclophosphamide
- Drug: Fludara — also filed as Fludarabine
Primary outcome
what the primary-completion date above is the date OFOccurrence of Dose Limiting Toxicities
measured Up to 36 days post-infusion.
Permalink · CYAD.BR's whole pipeline · Catalyst calendar · Every registered study · What changed